The Pricing Evolution of Personalized MedicinesVideo Categories: Pricing
PMO is pleased to offer the department “The Biomarker” to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. This month, we focus on KIT mutations in melanoma patients. Dr Sanjiv Agarwala provides his insights on this provocative topic.
Dr Sunil Verma identifies how he makes treatment decisions for his patients, noting that he tends to use endocrine treatments instead of chemotherapy.